Cost-effectiveness of obeticholic acid for the treatment of non-alcoholic steatohepatitis: An early economic evaluation

被引:3
作者
Chanh-Phong Tran [1 ]
Kim, John J. [1 ]
Feld, Jordan J. [2 ]
Wong, William W. L. [1 ]
机构
[1] Univ Waterloo, Fac Sci, Sch Pharm, PHR4011,10A Victoria St S, Kitchener, ON N2G 1C5, Canada
[2] Univ Hlth Network, Univ Toronto, Toronto Ctr Liver Dis, Toronto, ON, Canada
来源
CANADIAN LIVER JOURNAL | 2021年 / 4卷 / 04期
基金
加拿大健康研究院; 加拿大自然科学与工程研究理事会;
关键词
cost-utility analysis; non-alcoholic steatohepatitis; obeticholic acid; FATTY LIVER-DISEASE; HEPATOCELLULAR-CARCINOMA; UNITED-STATES; BURDEN; EPIDEMIOLOGY; ASSOCIATION; MANAGEMENT; CIRRHOSIS; OUTCOMES; SCORES;
D O I
10.3138/canlivj-2021-0011
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND: Currently, there are no pharmacological options available for the treatment of non-alcoholic steatohepatitis (NASH). In the 18-month interim analysis of an ongoing randomized, placebo-controlled phase 3 trial (REGENERATE), early results demonstrated that obeticholic acid (OCA) 25 mg significantly improved fibrosis with no worsening of NASH among patients with NASH and fibrosis compared with placebo (PBO). This study aimed to assess the potential cost-effectiveness of OCA compared with PBO in NASH patients. METHODS: A state-transition model was developed to perform a cost-utility analysis comparing two treatment strategies, PBO and OCA 25 mg, from a Canadian public payer perspective. The model time horizon was lifetime with annual cycle lengths. Cost and utility parameters were discounted at 1.5% annually. The efficacy data were obtained from the REGENERATE trial, and costs and utilities were derived from other published literature. Probabilistic and deterministic sensitivity analyses were performed to test the robustness of the model. RESULTS: Treatment with OCA led to reductions of 3.58% in decompensated cirrhosis cases, 3.95% in hepatocellular carcinoma, 7.88% in liver transplant, and 6.01% in liver-related death. However, at an annual price of CAD $36,000, OCA failed to be cost-effective compared with PBO at an incremental cost-effectiveness ratio of $815,514 per quality-adjusted life year (QALY). An 88% reduction in drug price to an annual cost of $4,300 would make OCA cost-effective at a willingness-to-pay threshold of $50,000/QALY. CONCLUSIONS: OCA failed to be cost-effective compared with PBO, despite demonstrating clinical benefits due to a high drug cost. A significant price reduction would be needed to make the drug cost-effective.
引用
收藏
页码:360 / 369
页数:10
相关论文
共 30 条
[1]  
[Anonymous], PBAC Guidelines | 3A.1 Overview and rationale of the economic evaluation
[2]   The Incidence and Risk Factors of Hepatocellular Carcinoma in Patients with Nonalcoholic Steatohepatitis [J].
Ascha, Mustafa S. ;
Hanouneh, Ibrahim A. ;
Lopez, Rocio ;
Tamimi, Tarek Abu-Rajab ;
Feldstein, Ariel F. ;
Zein, Nizar N. .
HEPATOLOGY, 2010, 51 (06) :1972-1978
[3]   The Natural History of Nonalcoholic Fatty Liver Disease With Advanced Fibrosis or Cirrhosis: An International Collaborative Study [J].
Bhala, Neeraj ;
Angulo, Paul ;
van der Poorten, David ;
Lee, Eric ;
Hui, Jason M. ;
Saracco, Giorgio ;
Adams, Leon A. ;
Charatcharoenwitthaya, Phunchai ;
Topping, Joanne H. ;
Bugianesi, Elisabetta ;
Day, Christopher P. ;
George, Jacob .
HEPATOLOGY, 2011, 54 (04) :1208-1216
[4]  
CADTH, 2017, CADTH COMM DRUG REV
[5]  
Canadian Liver Foundation, 2020, NON ALC STEAT NASH
[6]  
Cape JD, 2013, UNIV TOR MED J, V90, P103
[7]   The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases [J].
Chalasani, Naga ;
Younossi, Zobair ;
Lavine, Joel E. ;
Charlton, Michael ;
Cusi, Kenneth ;
Rinella, Mary ;
Harrison, Stephen A. ;
Brunt, Elizabeth M. ;
Sanyal, Arun J. .
HEPATOLOGY, 2018, 67 (01) :328-357
[8]   Frequency and Outcomes of Liver Transplantation for Nonalcoholic Steatohepatitis in the United States [J].
Charlton, Michael R. ;
Burns, Justin M. ;
Pedersen, Rachel A. ;
Watt, Kymberly D. ;
Heimbach, Julie K. ;
Dierkhising, Ross A. .
GASTROENTEROLOGY, 2011, 141 (04) :1249-1253
[9]   Health utilities and psychometric quality of life in patients with early- and late-stage hepatitis C virus infection [J].
Hsu, Priscilla C. ;
Federico, Carole A. ;
Krajden, Mel ;
Yoshida, Eric M. ;
Bremner, Karen E. ;
Anderson, Frank H. ;
Weiss, Alan A. ;
Krahn, Murray D. .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 27 (01) :149-157
[10]  
Institute for Clinical and Economic Review (ICER), 2020, OB AC TREATM NON STE